Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS

Core Insights - Oculis Holding AG announced positive results from the Phase 2 ACUITY trial for Privosegtor (OCS-05) in treating acute optic neuritis, showing improved low contrast visual acuity and preservation of retinal ganglion cells [1][2][3] Company Overview - Oculis is a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases, with a late-stage clinical pipeline that includes three core product candidates: OCS-01, Privosegtor (OCS-05), and Licaminlimab (OCS-02) [6] Trial Details - The ACUITY trial was a multicenter randomized placebo-controlled double-masked study, with results indicating a clinically meaningful improvement in vision by 18 letters at 3 months, alongside a favorable safety profile [2][3] - The trial results will be presented at the ECTRIMS 2025 Congress, highlighting the potential of Privosegtor in neuroprotection and its applicability in various neurological diseases [2] Drug Information - Privosegtor (OCS-05) is a novel peptoid small molecule candidate with neuroprotective properties, showing anatomical preservation of the retina and improvements in visual function in patients with acute optic neuritis [3][4] - The drug has received orphan drug designation from both the FDA and EMA for acute optic neuritis, indicating its potential for broader applications in neuro-ophthalmic and neurological conditions [3] Condition Overview - Acute optic neuritis is a rare condition affecting up to 8 in 100,000 people globally, often serving as the first sign of multiple sclerosis, primarily affecting adults aged 20 to 40, with a higher prevalence in women [5]